Potential Treatment of Cardiac Hypertrophy and Heart Failure by Inhibiting the Sarcolemmal Binding of Phospholipase C&bgr;1b

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|11|8|1032-1040

ISSN： 1389-4501

Source： Current Drug Targets, Vol.11, Iss.8, 2010-08, pp. : 1032-1040

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Role of PPARs in Pathological Cardiac Hypertrophy and Heart Failure

By  

Current Pharmaceutical Design, Vol. 23, Iss. 11, 2017-05 ,pp. : 1677-1686

Bentham Science Publishers

Access to resources Recommend Favorite

Vitamin D Therapy in Cardiac Hypertrophy and Heart Failure

By  

Current Pharmaceutical Design, Vol. 17, Iss. 18, 2011-06 ,pp. : 1794-1807

Bentham Science Publishers

Access to resources Recommend Favorite

Expression of protein kinase C isoforms in cardiac hypertrophy and heart failure due to volume overload

By Sentex Emmanuelle   Wang Xi   Liu Xueliang   Lukas Anton   Dhalla Naranjan S.  

Canadian Journal of Physiology and Pharmacology, Vol. 84, Iss. 2, 2006-02 ,pp. : 227-238

NRC Research Press

Access to resources Recommend Favorite

Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure

By  

Current Pharmaceutical Design, Vol. 17, Iss. 18, 2011-06 ,pp. : 1818-1824

Bentham Science Publishers

Access to resources Recommend Favorite

Research Highlights: &bgr;1- and α2C-adrenergic receptor polymorphisms and the antiarrhythmic effect of bucindolol in heart failure with reduced ejection fraction

By Lymperopoulos Anastasios   Negussie Shmuel   Walklett Karlee  

Pharmacogenomics, Vol. 14, Iss. 13, 2013-10 ,pp. : 1545-1549

Future Medicine

Access to resources Recommend Favorite